Prenatal management of the fetus with isolated congenital diaphragmatic hernia in the era of the TOTAL trial

Semin Fetal Neonatal Med. 2014 Dec;19(6):338-48. doi: 10.1016/j.siny.2014.09.006. Epub 2014 Nov 11.

Abstract

Congenital diaphragmatic hernia (CDH) may be isolated or associated with other structural anomalies, the latter with poor prognosis. The defect allows viscera to herniate through the defect into the chest, competing for space with the developing lungs. At birth, pulmonary hypoplasia leads to respiratory insufficiency and persistent pulmonary hypertension that is lethal in up to 30% of patients. When isolated, survival chances can be predicted by antenatal measurement of lung size and liver herniation. Chromosomal microarrays and exome sequencing contribute to understanding genetic factors underlying isolated CDH. Prenatal intervention aims at stimulating lung development, clinically achieved by percutaneous fetal endoscopic tracheal occlusion (FETO) under local anesthesia. The Tracheal Occlusion To Accelerate Lung growth trial (www.totaltrial.eu) is an international randomized trial investigating the role of fetal therapy for severe and moderate pulmonary hypoplasia. Despite an apparent increase in survival following FETO, the search for lesser invasive and more potent prenatal interventions must continue.

Keywords: Chromosomal microarrays; Congenital diaphragmatic hernia; Exome sequencing; Fetal surgery; Pulmonary hypoplasia; Tracheal occlusion.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Disease Management
  • Female
  • Fetoscopy*
  • Fetus / surgery*
  • Hernias, Diaphragmatic, Congenital / diagnosis
  • Hernias, Diaphragmatic, Congenital / surgery*
  • Humans
  • Lung / abnormalities*
  • Pregnancy
  • Treatment Outcome
  • Ultrasonography, Prenatal